# To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT05442060** · PHASE2 · RECRUITING · sponsor: **OBI Pharma, Inc** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** 30 μg OBI-833/100 μg OBI-821
- **DRUG:** Erlotinib (150 mg daily)

## Key facts

- **NCT ID:** NCT05442060
- **Lead sponsor:** OBI Pharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442060, "To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05442060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*